MARKET

AGEN

AGEN

Agenus
NASDAQ
2.560
-0.010
-0.39%
After Hours: 2.540 -0.02 -0.78% 19:59 02/06 EST
OPEN
2.580
PREV CLOSE
2.570
HIGH
2.670
LOW
2.540
VOLUME
2.86M
TURNOVER
0
52 WEEK HIGH
3.370
52 WEEK LOW
1.250
MARKET CAP
724.12M
P/E (TTM)
-3.2008
1D
5D
1M
3M
1Y
5Y
Analysts Are Bullish on These Healthcare Stocks: Agenus (AGEN), Danaher (DHR)
TipRanks · 01/25 13:30
Agenus' Updated Data Confirms Long-Term Potential Value
Seeking Alpha · 01/24 14:51
Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate
Benzinga · 01/23 19:33
Agenus Says Trial Results Showed 'Durable Responses' of Botensilimab, Balstilimab Combination in Colorectal Cancer
Agenus Says Trial Results Showed 'Durable Responses' of Botensilimab, Balstilimab Combination in Colorectal Cancer
MT Newswires · 01/23 15:36
Agenus (AGEN) Gets a Buy from B.Riley Financial
TipRanks · 01/23 12:45
Agenus Presents Clinical Data Demonstrating Durable Responses Of Botensilimab/Balstilimab Combination In Metastatic Microsatellite Stable Colorectal Cancer At ASCO GI
Benzinga · 01/23 12:31
B.Riley Financial Keeps Their Buy Rating on Agenus (AGEN)
TipRanks · 01/09 12:35
Agenus Registers for Potential Secondary Offering of Up to 2 Million Common Shares
Agenus Registers for Potential Secondary Offering of Up to 2 Million Common Shares
MT Newswires · 12/27/2022 03:49
More
About AGEN
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. It is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.